Novartis closed 2025 with net sales of $54.5 billion, up 8% in constant currencies, core operating income up 14%, and a core margin at 40.1%. The quarter told a more complicated story: Q4 sales slipped 1% at constant currencies as U.S. generic erosion and revenue deduction adjustments weighed on Entresto and Promacta, even as core operating income edged up 1%. The company proposed a 5.7% dividend increase to CHF 3.70 per share and guided to low single-digit net sales growth and a low single-digit decline in core operating income for 2026. Growth continues to be anchored by priority brands—Kisqali, Kesimpta, Pluvicto, Scemblix, and Cosentyx—while the pipeline advanced with an FDA approval for Itvisma in a broad SMA population, EU first-line expansion for Scemblix in CML, and a U.S. filing for Pluvicto in metastatic hormone-sensitive prostate cancer. Novartis also moved to acquire Avidity Biosciences to secure a differentiated RNA delivery platform and late-stage neuromuscular programs, with closing expected in the first half of 2026.
The signal is clear: Novartis is attempting to grow through what it characterizes as the largest patent expiry in its history, while absorbing pricing concessions in the U.S. through a newly announced government agreement. That mix of headwinds and pipeline momentum sets up a decisive year for execution. Commercial teams face a two-front campaign—defending against erosion while pushing earlier-line adoption and label expansions—at the very moment U.S. price pressure is shifting from policy risk to operating reality.
For patients, the immediate impact is increased access to differentiated options across oncology, immunology, and neuroscience. Kisqali continues to accelerate with adjuvant data in early breast cancer, potentially reshaping recurrence-risk conversations. Pluvicto’s bid to move into hormone-sensitive disease could expand radioligand therapy upstream, contingent on manufacturing scale and diagnostic pathways that reliably identify PSMA-positive populations. Itvisma’s broad SMA approval and Fabhalta’s momentum in IgAN and C3G extend the company’s reach into high-burden conditions, but payer engagement will hinge on long-term outcomes and budget predictability.
Payers will scrutinize duration, sequencing, and total cost of care. The U.S. price agreement—now embedded in 2026 guidance and a five-year sales CAGR target of 5–6%—raises the bar for evidentiary packages that link earlier-line use to downstream savings. Medical Affairs will be central to generating real-world data, particularly for radioligands and gene therapies where persistence, adherence, and diagnostic infrastructure drive value realization as much as efficacy. Expect intensified focus on outcomes-based frameworks and site-of-care strategies for complex modalities.
Competitors should read Novartis’s moves as a durable bet on hard-to-replicate platforms. Radioligand therapy scale-up (Pluvicto, Lutathera), gene and cell therapy (Itvisma), and RNA-targeting via the Avidity deal fit a broader industry pattern: large pharmas consolidating manufacturing moats and delivery know-how while small biotechs struggle to finance late-stage development. The company’s ongoing share buybacks and strong free cash flow underscore capacity to fund both BD and launch muscle, but guidance implies margin pressure as pricing and LOE collide.
The strategic question is whether Novartis can convert pipeline catalysts into revenue fast enough to offset pricing concessions and expiries, without sacrificing margin discipline. Early-line wins for Kisqali and Pluvicto will test payer tolerance for higher upfront spend, while Avidity’s DM1 and FSHD programs will test the speed at which novel RNA delivery can translate into approvable, reimbursable labels. If the U.S. price framework previewed here becomes an industry template, will platform defensibility and launch excellence be sufficient to sustain double-digit growth brands in a single-digit growth market, or will biopharma business models need to bend further toward risk-sharing to keep innovation funded at scale?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
